Metabolism Unit, Massachusetts General Hospital, Boston, Massachusetts, USA.
Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, USA.
J Infect Dis. 2022 Feb 15;225(4):603-607. doi: 10.1093/infdis/jiab575.
Little is known regarding coronavirus disease 2019 (COVID-19) vaccination rates in people with HIV (PWH), a vulnerable population with significant morbidity from COVID-19. We assessed COVID-19 vaccination rates among 6952 PWH in the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) compared to region- and country-specific vaccination data. The global probability of COVID-19 vaccination through end of July 2021 was 55% among REPRIEVE participants with rates varying substantially by Global Burden of Disease (GBD) superregion. Among PWH, factors associated with COVID-19 vaccination included residence in high-income regions, age, white race, male sex, body mass index, and higher cardiovascular risk. Clinical Trials Registration. NCT02344290.
关于 2019 年冠状病毒病（COVID-19）在艾滋病毒感染者（PWH）中的疫苗接种率知之甚少，而 PWH 是 COVID-19 发病率较高的脆弱人群。我们评估了在预防艾滋病毒血管事件的随机试验（REPRIEVE）中 6952 名 PWH 中的 COVID-19 疫苗接种率与区域和国家特定的疫苗接种数据相比。到 2021 年 7 月底，REPRIEVE 参与者中 COVID-19 疫苗接种的全球概率为 55%，其比例因全球疾病负担（GBD）超区域而有很大差异。在 PWH 中，COVID-19 疫苗接种的相关因素包括居住在高收入地区、年龄、白种人、男性、体重指数和更高的心血管风险。临床试验注册。NCT02344290。
